Endostatin Polyclonal Antibody, Invitrogen™

Description

• PA1-601 detects recombinant human and mouse endostatin
• PA1-601 has been successfully used in Western blot, IF/ICC and IHC (P) procedures
• By Western blot, this antibody detects a 20 kDa protein representing recombinant human endostatin
• PA1-601 immunizing peptides are two peptides derived from mouse and human endostatin protein corresponding to amino acid residues 129-142 of endostatin
• PA1-601 can be used with blocking peptide PEP-112
• Endostatin is able to avoke non-uniform response for proliferation, cell mount and migration of entothelial cells, which different endostatin binding characteristic, leads to the assumption that endostatin effect is strongly dependent from endothelial cell type
• Furthermore endostatin inhibits angiogenesis and tumor growth in vivo by inducing apoptosis in endothelial cells
• The local delivery of endostatin seems to specifically affect tumor-associated microvessels by reduction of the vessel density, diameter and functionality
• Tumor cell migration and invasion was greatly reduced in the endostatin treated animals
• Endostatin is non-toxic and does not induce aquired drug resistance and has therefor become a potent new therapy strategy in solid neoplasias
• This therapy appears to have a high potential not only for the treatment of gliomas, the most common brain tumors, but also in other tumors
• The ability of endostatin to inhibit neoangiogenesis is mediated, at least in part, by Zn^+2 binding and elastase processing
• Widespread endostatin expression was found in elactic fibers in vessel walls and in some other basement membrane zones
• Endostatin is released by neurons to accumulate in amyloid plaques in Alzheimer's disease.